C18 Ganglioside GM2-d7 (d18:1/18:0-d7) is intended for use as an internal standard for the quantification of C18 ganglioside GM2 by GC- or LC-MS. C18 Ganglioside GM2 is a monosialylated ganglioside found in the mammalian brain where it is localized to the cell membrane.[1] It accumulates in Tay-Sachs and Sandhoff disease, which are neurodegenerative disorders characterized by deficiency of lysosomal β-hexosaminidase A and B, respectively.[2] Ganglioside GM2 disrupts the function of immune cells and, when used at a concentration of 25 µM, increases migration and invasion of SK-RC-45 cells with no effect on proliferation.[3] This product is fully synthetic and has no variations in the fatty acyl chain or sphingoid backbone. It is intended for use as an analytical standard for the quantification of C18 ganglioside GM2 by GC-MS.
References:
[1].Schnaar, R.L.Gangliosides of the vertebrate nervous systemJ. Mol. Biol.428(16)3325-3336(2016).
[2].Baek, R.C., Martin, D.R., Cox, N.R., et al.Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff diseaseLipids44(3)197-205(2009).
[3].Kundu, M., Mahata, B., Banerjee, A., et al.Ganglioside GM2 mediates migration of tumor cells by interacting with integrin and modulating the downstream signaling pathwayBiochim. Biophys. Acta1863(7 Pt A)1472-1489(2016).